Star Combo Pharma Limited

ASX:S66 Stock Report

Market Cap: AU$18.9m

Star Combo Pharma Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Su Zhang

Chief executive officer

AU$209.7k

Total compensation

CEO salary percentage90.1%
CEO tenure6.9yrs
CEO ownership8.5%
Management average tenureno data
Board average tenure6.8yrs

Recent management updates

Recent updates

Some Star Combo Pharma Limited (ASX:S66) Shareholders Look For Exit As Shares Take 31% Pounding

Nov 11
Some Star Combo Pharma Limited (ASX:S66) Shareholders Look For Exit As Shares Take 31% Pounding

Star Combo Pharma Limited's (ASX:S66) 30% Share Price Surge Not Quite Adding Up

Aug 23
Star Combo Pharma Limited's (ASX:S66) 30% Share Price Surge Not Quite Adding Up

Star Combo Pharma (ASX:S66) Might Have The Makings Of A Multi-Bagger

Aug 13
Star Combo Pharma (ASX:S66) Might Have The Makings Of A Multi-Bagger

Star Combo Pharma Limited's (ASX:S66) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 12
Star Combo Pharma Limited's (ASX:S66) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Star Combo Pharma (ASX:S66) Is Doing The Right Things To Multiply Its Share Price

May 12
Star Combo Pharma (ASX:S66) Is Doing The Right Things To Multiply Its Share Price

Star Combo Pharma Limited's (ASX:S66) Shares May Have Run Too Fast Too Soon

Mar 20
Star Combo Pharma Limited's (ASX:S66) Shares May Have Run Too Fast Too Soon

Should Shareholders Have Second Thoughts About A Pay Rise For Star Combo Pharma Limited's (ASX:S66) CEO This Year?

Nov 21
Should Shareholders Have Second Thoughts About A Pay Rise For Star Combo Pharma Limited's (ASX:S66) CEO This Year?

Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think

Mar 02
Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think

Rock star Growth Puts Star Combo Pharma (ASX:S66) In A Position To Use Debt

Dec 24
Rock star Growth Puts Star Combo Pharma (ASX:S66) In A Position To Use Debt

CEO Compensation Analysis

How has Su Zhang's remuneration changed compared to Star Combo Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$210kAU$189k

AU$747k

Mar 31 2024n/an/a

AU$616k

Dec 31 2023n/an/a

AU$485k

Sep 30 2023n/an/a

-AU$2m

Jun 30 2023AU$196kAU$170k

-AU$4m

Mar 31 2023n/an/a

-AU$5m

Dec 31 2022n/an/a

-AU$5m

Sep 30 2022n/an/a

-AU$3m

Jun 30 2022AU$194kAU$172k

-AU$696k

Mar 31 2022n/an/a

-AU$5m

Dec 31 2021n/an/a

-AU$8m

Sep 30 2021n/an/a

-AU$8m

Jun 30 2021AU$182kAU$163k

-AU$8m

Mar 31 2021n/an/a

-AU$3m

Dec 31 2020n/an/a

AU$1m

Sep 30 2020n/an/a

AU$533k

Jun 30 2020AU$169kAU$153k

-AU$349k

Mar 31 2020n/an/a

-AU$990k

Dec 31 2019n/an/a

-AU$2m

Sep 30 2019n/an/a

-AU$2m

Jun 30 2019AU$164kAU$150k

-AU$2m

Mar 31 2019n/an/a

-AU$2m

Dec 31 2018n/an/a

-AU$3m

Sep 30 2018n/an/a

-AU$2m

Jun 30 2018AU$93kAU$85k

-AU$2m

Compensation vs Market: Su's total compensation ($USD131.05K) is below average for companies of similar size in the Australian market ($USD292.84K).

Compensation vs Earnings: Su's compensation has been consistent with company performance over the past year.

CEO

Su Zhang

6.9yrs

Tenure

AU$209,701

Compensation

Ms. Su Zhang, MBA, GradCertComm, BPharm serves as Chief Executive Officer at Star Combo Pharma Ltd since November 2018 and serves as its Executive Director since 2018. She served as Director at Star Combo...

Board Members

NamePositionTenureCompensationOwnership
Su Zhang
CEO & Executive Director6.9yrsAU$209.70k8.48%
A$ 1.6m
JinXing Zhang
Founder8.1yrsAU$199.83k28.25%
A$ 5.3m
Richard Allely
Independent Non-Executive Chairman6.8yrsAU$101.37kno data
Wei Han
Non Executive Director4.6yrsno datano data
Jialong Ding
Non Executive Director4.6yrsno datano data

6.8yrs

Average Tenure

Experienced Board: S66's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 04:51
End of Day Share Price 2024/12/13 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Star Combo Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution